Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete. [More]
Newer class of diabetes medications may also improve cardiovascular health, researchers report

Newer class of diabetes medications may also improve cardiovascular health, researchers report

A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported in a new meta-analysis presented yesterday at the American Society of Hypertension's Annual Scientific Meeting and Exposition. [More]
FDA approves Mylan's ANDA for Fenofibrate Tablets

FDA approves Mylan's ANDA for Fenofibrate Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. [More]
People suffering from PTSD have risk of developing type 2 diabetes

People suffering from PTSD have risk of developing type 2 diabetes

The presence of posttraumatic stress disorder is significantly associated with the development of type 2 diabetes. This is the finding of scientists from the Helmholtz Zentrum München and the University Hospital Gieβen and Marburg who worked with data from the population-based KORA cohort study. [More]
Regular marijuana use is associated with favorable indices related to diabetic control, say investigators

Regular marijuana use is associated with favorable indices related to diabetic control, say investigators

Regular marijuana use is associated with favorable indices related to diabetic control, say investigators. They found that current marijuana users had significantly lower fasting insulin and were less likely to be insulin resistant, even after excluding patients with a diagnosis of diabetes mellitus. Their findings are reported in the current issue of The American Journal of Medicine. [More]
Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial. [More]

Abbott receives CE Mark for ARCHITECT HbA1c test

Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c test, which may aid physicians in diagnosing and monitoring diabetes as well as identifying patients at risk for developing diabetes. [More]

Researchers develop new method for continuous glucose monitoring in patients with type 1 diabetes

Researchers at the Universitat Politècnica de València and the Universitat de Girona have developed a new method for continuous glucose monitoring in patients with type 1 diabetes. [More]
EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

EPAC stands for exchange protein activated by cyclic AMP (cAMP). cAMP is an (among many) intracellular messenger molecule. cAMP is generated when certain hormones stimulate a cell by binding to their receptor, which is at the outside surface of the cell. [More]

Boehringer Ingelheim Pharmaceuticals, Eli Lilly launch SGLT disease education initiative

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the launch of an educational campaign designed to provide healthcare professionals with a greater understanding of the role sodium glucose co-transporters play in maintaining blood sugar balance, or glucose homeostasis. [More]
Scientists reveal that exposure to everyday noise may affect cardiovascular system

Scientists reveal that exposure to everyday noise may affect cardiovascular system

Exposure to noise, for example from road traffic, may adversely affect the cardiovascular system. Until now, underlying mechanisms linking noise to elevated cardiovascular risk have rarely been explored in epidemiological studies. Scientists of Helmholtz Zentrum München have now shown that exposure to noise during everyday life influences heart rate variability, i.e. the ability of the heart to adjust the rate at which it beats to acute events. [More]
Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use. [More]
Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. [More]

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013. [More]
Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others. [More]

AACE publishes comprehensive diabetes management algorithm to treat prediabetes, T2DM patients

The American Association of Clinical Endocrinologists today announced the publication of its comprehensive diabetes management algorithm created to guide primary care physicians, endocrinologists and other health care professionals in the treatment of prediabetes and type 2 diabetes mellitus patients. [More]
Study: Mediterranean diet associated with lower risk of hyperuricemia in older adults

Study: Mediterranean diet associated with lower risk of hyperuricemia in older adults

According to a study published in the Journals of Gerontology Series A: Biological Sciences and Medical Sciences, a baseline adherence to a Mediterranean diet (MeDiet) is associated with a lower risk of hyperuricemia, defined as a serum uric acid (SUA) concentration higher than 7mg/dl in men and higher than 6mg/dl in women. [More]
Obesity epidemic in the Asia Pacific region: an interview with Prof Drexel, European Society of Cardiology

Obesity epidemic in the Asia Pacific region: an interview with Prof Drexel, European Society of Cardiology

The prevalence of obesity is about 20 % in Australia, 17 % in Japan, but only 3 – 4 % in China. Thus, Asia Pacific is a very heterogeneous region. [More]
Study: Glycated hemoglobin levels of children with type 1 diabetes are correlated negatively with household income

Study: Glycated hemoglobin levels of children with type 1 diabetes are correlated negatively with household income

Researchers at the University of Montreal have found that the glycated hemoglobin levels of children with type 1 diabetes followed at its affiliated Sainte-Justine Mother and Child University Hospital (CHU Sainte-Justine) is correlated linearly and negatively with household income. [More]
Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive data for collagenase clostridium histolyticum or CCH which is being developed for the potential treatment, if approved by the U.S. Food and Drug Administration, of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome. [More]